Science Explorer Back to mapMap
Discussion
Company · Wilmington · United States

Sun Pharma (United States)

sunpharma.com/usaROR OpenAlex
Research works
35
▼ 31% vs 2018-21
Citations
329
9.5 per fractional work
Top-10% rate
9.9%
all institutions 10.0%
Open access
56%
world 40%
International
39%
world 18%
Sun Pharma (United States)

Not ranked overall: Sun Pharma (United States) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Sun Pharma (United States) work in?

In all years, 62% of research at Sun Pharma (United States) is in Health Sciences, 26% in Life Sciences. Its largest fields are Medicine (62%), Immunology and Microbiology (14%), Biochemistry, Genetics and Molecular Biology (6%). It does 2.2× the world's share of Health Sciences.

Health Sciences: 22 fractional works · 62.3% of its workMedicine: 21 fractional works · 61.5% of its workDermatology: 4 fractional works · 10.7% of its workPublic Health, Environmental and Occupational Health: 3 fractional works · 7.4% of its workRheumatology: 2 fractional works · 6.5% of its workOphthalmology: 1 fractional works · 3.8% of its workRadiology, Nuclear Medicine and Imaging: 1 fractional works · 3.6% of its workPediatrics, Perinatology and Child Health: 1 fractional works · 3.2% of its workOncology: 1 fractional works · 3.2% of its workImmunology and Allergy: 1 fractional works · 3.1% of its workHematology: 1 fractional works · 2.7% of its workPathology and Forensic Medicine: 1 fractional works · 2.6% of its workEpidemiology: 1 fractional works · 2.4% of its workPulmonary and Respiratory Medicine: 1 fractional works · 2.4% of its workPhysiology: 1 fractional works · 1.8% of its workSurgery: 0 fractional works · 1.2% of its workEndocrinology, Diabetes and Metabolism: 0 fractional works · 1.1% of its workPharmacology: 0 fractional works · 0.9% of its workNeurology: 0 fractional works · 0.7% of its workPsychiatry and Mental health: 0 fractional works · 0.7% of its workEmergency Medicine: 0 fractional works · 0.5% of its workCardiology and Cardiovascular Medicine: 0 fractional works · 0.5% of its workHepatology: 0 fractional works · 0.5% of its workInternal Medicine: 0 fractional works · 0.5% of its workUrology: 0 fractional works · 0.4% of its workNephrology: 0 fractional works · 0.3% of its workInfectious Diseases: 0 fractional works · 0.3% of its workOtorhinolaryngology: 0 fractional works · 0.3% of its workHealth Professions: 0 fractional works · 0.3% of its workGeneral Health Professions: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.1% of its workNursing: 0 fractional works · 0.3% of its workNutrition and Dietetics: 0 fractional works · 0.3% of its workDentistry: 0 fractional works · 0.1% of its workLife Sciences: 9 fractional works · 26.5% of its workImmunology and Microbiology: 5 fractional works · 13.8% of its workImmunology: 5 fractional works · 13.6% of its workSmaller subfields together: 0 fractional works · 0.2% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 6.4% of its workMolecular Biology: 2 fractional works · 5.5% of its workGenetics: 0 fractional works · 0.6% of its workCell Biology: 0 fractional works · 0.3% of its workPharmacology, Toxicology and Pharmaceutics: 2 fractional works · 5.2% of its workPharmaceutical Science: 1 fractional works · 3.8% of its workPharmacology: 0 fractional works · 1.4% of its workNeuroscience: 0 fractional works · 1.0% of its workCellular and Molecular Neuroscience: 0 fractional works · 0.3% of its workNeurology: 0 fractional works · 0.3% of its workSmaller subfields together: 0 fractional works · 0.3% of its workPhysical Sciences: 3 fractional works · 7.3% of its workEngineering: 2 fractional works · 4.9% of its workBiomedical Engineering: 2 fractional works · 4.4% of its workSmaller subfields together: 0 fractional works · 0.4% of its workChemistry: 0 fractional works · 1.4% of its workOrganic Chemistry: 0 fractional works · 0.8% of its workAnalytical Chemistry: 0 fractional works · 0.3% of its workSpectroscopy: 0 fractional works · 0.3% of its workMaterials Science: 0 fractional works · 0.7% of its workMaterials Chemistry: 0 fractional works · 0.4% of its workBiomaterials: 0 fractional works · 0.3% of its workComputer Science: 0 fractional works · 0.3% of its workComputational Theory and Mathematics: 0 fractional works · 0.3% of its workSocial Sciences: 1 fractional works · 3.9% of its workEconomics, Econometrics and Finance: 1 fractional works · 3.9% of its workEconomics and Econometrics: 1 fractional works · 3.9% of its workALL ITS WORKSun Pharma(United States)35fractional works, all years
Life Sciences26%Physical Sciences7%Health Sciences62%Social Sciences4%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 13 fields, with their numbers
    1. Medicine2161.5%
    2. Health Professions00.3%
    3. Nursing00.3%
    4. Dentistry00.1%
    1. Immunology and Microbiology513.8%
    2. Biochemistry, Genetics and Molecular Biology26.4%
    3. Pharmacology, Toxicology and Pharmaceutics25.2%
    4. Neuroscience01.0%
    1. Engineering24.9%
    2. Chemistry01.4%
    3. Materials Science00.7%
    4. Computer Science00.3%
    1. Economics, Econometrics and Finance13.9%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Biochemistry, Genetics and Molecular Biology: 0.85× its world share, 0 worksBiochemistry, Geneti…Immunology and Microbiology: 18.07× its world share, 2 worksImmunology and Micro…Neuroscience: 1.18× its world share, 0 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 4.15× its world share, 0 worksPharmacology, Toxico…Engineering: 0.11× its world share, 0 worksEngineeringMaterials Science: 0.16× its world share, 0 worksMaterials ScienceHealth Professions: 0.38× its world share, 0 worksHealth ProfessionsMedicine: 3.46× its world share, 8 worksMedicineEconomics, Econometrics and Finance: 1.96× its world share, 0 worksEconomics, Econometr…1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 18.1×. Every wedge is a field page.

All 9 fields, with their numbers
  1. Immunology and Microbiology18.07×2 works
  2. Pharmacology, Toxicology and Pharmaceutics4.15×0 works
  3. Medicine3.46×8 works
  4. Economics, Econometrics and Finance1.96×0 works
  5. Neuroscience1.18×0 works
  6. Biochemistry, Genetics and Molecular Biology0.85×0 works
  7. Health Professions0.38×0 works
  8. Materials Science0.16×0 works
  9. Engineering0.11×0 works

Who are the top researchers at Sun Pharma (United States)?

Ranked on the quality score, Alan M. Mendelsohn, Abayomi Ogundele and Stephen J. Rozzo lead among researchers whose main affiliation is Sun Pharma (United States).

  1. 1 Alan M. Mendelsohn United States · #724,337 worldwide 5.5k citations · 132 works
  2. 2 Abayomi Ogundele United States · #2,618,583 worldwide 1.1k citations · 40 works
  3. 3 Stephen J. Rozzo United States · #2,646,368 worldwide 2.7k citations · 98 works
  4. 4 Simon Lowry United States · #3,520,230 worldwide 282 citations · 24 works
  5. 5 Jeffrey R. Parno United States · #3,933,518 worldwide 320 citations · 24 works
  6. 6 Nicholas A. Squittieri United States · #5,983,318 worldwide 434 citations · 62 works
All ranked researchers at Sun Pharma (United States)

What are the most cited papers from Sun Pharma (United States)?

The most cited paper from Sun Pharma (United States) is "Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease" (Abhirup Mandal, Vrinda Gote, Dhananjay Pal et al., 2019), with 157 citations. Next come "A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease" (110) and "Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)" (101).

Most cited papers
#PaperReleasedCitations
1 Ocular Pharmacokinetics of a Topical Ophthalmic Nanomicellar Solution of Cyclosporine (Cequa®) for Dry Eye Disease Abhirup Mandal, Vrinda Gote, Dhananjay Pal et al. · Pharmaceutical Research 7 Jan 2019 157
2 A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease Damien F. Goldberg, Ranjan P. Malhotra, Barry A. Schechter et al. · Ophthalmology Open access 6 Apr 2019 110
3 Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1) Brett King, Maryanne Makredes Senna, Natasha Atanaskova Mesinkovska et al. · Journal of the American Academy of Dermatology Open access 23 Jul 2024 101
4 Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)* Diamant Thaçi, Stefano Piaserico, Richard Bruce Warren et al. · British Journal of Dermatology Open access 8 Feb 2021 101
5 MR-guided Focused Ultrasound Facilitates Sonodynamic Therapy with 5-Aminolevulinic Acid in a Rat Glioma Model Sheng‐Kai Wu, Marc A. Santos, Stuart L. Marcus et al. · Scientific Reports Open access 18 Jul 2019 93
All 61 most cited papers, with filters and sorting

Which keywords describe research at Sun Pharma (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Inflammatory Cytokines, Epidemiology, Immune System, IL-17, TH17 Cells, Quality of Life, Inflammation and Dry Eye Disease.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 27 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 27 words, with their numbers
  1. Inflammatory Cytokines6▲ 265×2 topics
  2. Epidemiology6▲ 4.4×20 topics
  3. Immune System4▲ 40×2 topics
  4. IL-174▲ 505×1 topic
  5. TH17 Cells4▲ 505×1 topic
  6. Inflammation3▲ 3.7×13 topics
  7. Quality of Life3▲ 5.7×6 topics
  8. Dry Eye Disease2▲ 173×1 topic
  9. Ocular Surface2▲ 173×1 topic
  10. Cancer2▲ 4.1×7 topics
  11. Immune Dysregulation2▲ 65×2 topics
  12. Filaggrin2▲ 116×1 topic
  13. Skin Microbiome2▲ 116×1 topic
  14. Photodynamic Therapy2▲ 27×3 topics
  15. Ankylosing Spondylitis1▲ 179×1 topic
  16. Clinical Trials1▲ 6.6×5 topics
  17. Nanoparticles1▲ 3.1×5 topics
  18. Spondyloarthritis1▲ 179×1 topic
  19. Treatment1▲ 3.0×6 topics
  20. Antibiotic Resistance1▲ 9.6×2 topics
  21. Cost-effectiveness Analysis1▲ 48×1 topic
  22. Diagnosis1▲ 3.8×6 topics
  23. Health Utility Measures1▲ 48×1 topic
  24. Autoantibodies1▲ 13×5 topics
  25. Antioxidant1▲ 4.4×3 topics
  26. Antiviral1▲ 32×3 topics
  27. Drug Delivery1▲ 6.0×3 topics

Which research topics does Sun Pharma (United States) publish most on?

By volume in 2022-now: Psoriasis: Treatment and Pathogenesis, Chronic Myeloid Leukemia Treatments, Dermatology and Skin Diseases and Acne and Rosacea Treatments and Effects.

Psoriasis: Treatment and…2Psoriasis: Treatment and Pathogenesis: 2 fractional worksChronic Myeloid Leukemia…1Chronic Myeloid Leukemia Treatments: 1 fractional worksDermatology and Skin Dis…1Dermatology and Skin Diseases: 1 fractional worksAcne and Rosacea Treatments and Effects: 1 fractional worksSpondyloarthritis Studies and Treatments: 0 fractional worksHealth Systems, Economic…0Health Systems, Economic Evaluations, Quality of Life: 0 fractional worksOcular Surface and Contact Lens: 0 fractional worksAutoimmune Bullous Skin Diseases: 0 fractional worksContact Dermatitis and Allergies: 0 fractional worksCytokine Signaling Pathways and Interactions: 0 fractional works
ImmunologyHematologyDermatologyRheumatology4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Psoriasis: Treatment and Pathogenesis Immunology 2 works
  2. 2 Chronic Myeloid Leukemia Treatments Hematology 1 works
  3. 3 Dermatology and Skin Diseases Dermatology 1 works
  4. 4 Acne and Rosacea Treatments and Effects Dermatology 1 works
  5. 5 Spondyloarthritis Studies and Treatments Rheumatology 0 works
  6. 6 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 0 works
  7. 7 Ocular Surface and Contact Lens Public Health, Environmental and Occupational Health 0 works
  8. 8 Autoimmune Bullous Skin Diseases Pathology and Forensic Medicine 0 works
  9. 9 Contact Dermatitis and Allergies Dermatology 0 works
  10. 10 Cytokine Signaling Pathways and Interactions Oncology 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available55.9%not open44.1%

World: 40% of research is openly available.

with international co-authors39.1%domestic only60.9%

World: 18% is written across borders.

How has Sun Pharma (United States)'s research output changed?

Output in 2022-2025 was 31% lower than in 2018-2021.

still counting200020052010201520202025
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Sun Pharma (United States) as a percentage of every work published that year, 0.000039% in 2024.

still counting0.000050%0.00010%0.00015%Sun Pharma (United States)0.000071% in 2025200020102020

Fractional works of Sun Pharma (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Wilmington

All research institutions in Wilmington

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about Sun Pharma (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.